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ABSTRACT 
Persistent immune activation with premature ageing and increased risk of cardiovascular disease 
(CVD) are features shared by HIV-1 infected individuals and patients with chronic kidney disease 
(CKD). Underlying dysbiosis, a failing mucosal barrier function and microbial translocation (MT) 
are contributing factors in both conditions. Vitamin D supplementation might prove valuable by its 
modulatory effects on innate and adaptive immunity, including induction of antimicrobial peptides 
(AMPs), regulation of epithelial barrier integrity and gut microbial composition.  
The main objective of this thesis was to assess gut-derived immune activation and investigate the 
modulatory effects of vitamin D supplementation in HIV-1. Additionally we wanted to explore 
Trimethylamine-N-Oxid (TMAO), a microbial metabolite with newly ascribed pro-atherosclerotic 
properties, as a novel link between gut microbiome and inflammaging in CKD and in HIV-1. 
In an observational study on HIV-1 infected individuals on antiretroviral treatment (ART) and non-
HIV controls, we found that, whereas HIV-1 infected individuals demonstrated increased immune 
activation in the form of elevated levels of hsCRP and sCD14 with HIV as an independent risk 
factor, they did not differ from controls in degree of MT measured by LPS. 
We next assessed the role of TMAO in cross-sectional and retrospective cohorts of CKD and HIV-
1 patients of various disease stages. We found that TMAO levels correlated with increased systemic 
inflammation measured by hsCRP and was an independent predictor of mortality in CKD. TMAO 
levels were strongly associated with renal function and normalized after renal transplantation. In 
HIV-1, we found that TMAO levels were lower in untreated HIV-1 and normalized with treatment, 
but held no association with markers of immune activation or MT. Higher TMAO-levels in well 
controlled HIV-1 were not significantly associated with cardiovascular events. Nor was TMAO 
levels clearly associated with gut microbiome, or degree of dysbiosis. 
Finally, in a randomized, double-blind and placebo-controlled trial of daily supplementation with 
vitamin D and phenylbutyrate in treatment-naïve HIV-1 infected individuals, we found no 
significant effects on circulating immune activation markers or TMAO and kynurenine/tryptophan 
ratio. Nor was there a significant treatment effect on the colonic mucosal microbiome.  
In conclusion, vitamin D did not associate with biomarkers of immune activation in well controlled 
HIV-1. Further, we found no support that supplementation with vitamin D and PBA could modulate 
gut-derived immune activation and dysbiosis in treatment-naïve HIV-1. Our results suggest that 
TMAO may have a contributory role in immune activation and all-cause mortality in CKD. 
However, the role of TMAO in cardiovascular pathogenesis in CKD was not specifically addressed. 
Moreover, elevated TMAO levels were strongly related to kidney functions and the effects should 
be interpreted with caution. In HIV-1, or data did not support TMAO as a significant link between 
gut dysbiosis and inflammaging. TMAO levels were disparately confounded by HIV-1, microbial 
composition and ART, thus limiting its role as a cardiovascular marker in HIV-1. 
SAMMANFATTNING PÅ SVENSKA 
Kronisk inflammation bidrar till ett för tidigt åldrande med ökad risk för hjärt- och kärl 
sjukdom, både hos individer med HIV och kronisk njursvikt. En bidragande faktor till denna 
process är en rubbad (dysbiotisk) tarmflora och sviktande barriärfunktion i tarmväggen, vilket 
leder till ett inflöde av retande bakteriella produkter från tarmen.  
Kosttillskott med vitamin D kan skydda genom att påverka immunförsvaret med ökad 
frisättningen av antimikrobiella peptider som deltar i tarmväggens försvar mot invasiva 
patogener. Vitamin D-signalering stärker även tarmväggens barriärfunktion och tycks vidare 
kunna reglera tamflorans sammansättning.  
Syftet med detta doktorandprojekt var dels att studera om vitamin D-ersättning kan påverka 
tarmrelaterad inflammation och underliggande dysbios hos HIV-infekterade individer. Det 
andra målet var att studera om den bakteriella produkten Trimethylamine-N Oxid (TMAO) 
utgör en ny länk mellan tarmflora och tarmdriven inflammation i HIV-1 och kronisk njursvikt. 
TMAO är en metabolit som skapas av tarmbakterier. Den har kopplats till bildande av 
ateroskleros och är starkt associerad med ökad risk för hjärt- och kärl sjukdom i stora 
befolkningsstudier. 
I delstudie I studerade vi prevalens av vitamin D-brist, och kopplingen till biomarkörer för 
tarm-driven inflammation hos HIV-infekterade individer med pågående behandling, i 
jämförelse med en frisk kontrollgrupp. Vi fann att majoriteten hade lägre vitamin D-nivåer än 
vad som rekommenderas, men även att vitamin D nivåerna inte kunde sammankopplas med 
någon biomarkör för tarmrelaterad inflammation. HIV-infekterade individer skiljde sig inte 
avseende nivåer av LPS, som är en specifik markör för tarmrelaterad inflammation, men hade 
ökad grad av immunoaktivering mätbar i form av höjda nivåer av högkänsligt CRP (hsCRP) 
och sCD14 (en markör för monocyt och makrofag aktivering) jämfört med kontroller. 
I delstudie II och III studerade vi om cirkulerande TMAO utgör en länk mellan en dysbiotisk 
tarmflora, systemisk immunoaktivering och medför en ökad risk för mortalitet och hjärt- och 
kärl sjukdom i patienter med olika stadier av kronisk njursvikt (delstudie II) och HIV-1 
(delstudie III). Vi fann att förhöjda TMAO-nivåer korrelerade med ökad grad av systemisk 
inflammation mätt med hsCRP och var en oberoende prediktor för mortalitet hos njursjuka 
patienter. Vidare att TMAO nivåer var starkt kopplade till njurfunktion. I HIV fann vi att 
TMAO-nivåer var låga i obehandlade HIV-infekterade individer och normaliserades efter 
behandlingsstart, men även att nivåerna inte påverkades av immunstatus, val av behandling 
eller grad av systemisk inflammation i någon kohort. Vidare sågs ingen tydlig koppling mellan 
TMAO-nivåer och tarmflora vare sig vid behandlingsstart eller uppföljning. Slutligen, TMAO 
var inte signifikant kopplat till högre risk för hjärt- och kärl sjukdom hos HIV-infekterade 
individer med god viral kontroll. 
I delstudie IV, genomförde vi en randomiserad, dubbelblind och placebokontrollerad 
behandlingsstudie med vitamin D och phenylbyturate (PBA) bland obehandlade HIV-
infekterade individer i Etiopien. Vi studerade behandlingseffekt på tarmrelaterad inflammation 
och tarmflora med ett särskilt fokus på TMAO och tryptofan metabolism. Vi fann att 
behandlingskombinationen inte gav någon mätbar effekt på grad av inflammatorisk aktivering 
mätt med sCD14 och antimikrobiell peptid LL-37 trots ökade vitamin D nivåer. Det förelåg 
ingen skillnad avseende TMAO-nivå eller kynurenine/tryptofan-kvoter. Vidare sågs ingen 
effekt på tarmfloran vare sig avseende alfadiversitet (skillnad i mångfalden bakterier inom 
individen) eller betadiversitet (skillnaden i mångfald bakterier mellan individer eller grupper).  
Sammanfattningsvis så fann vi låga vitamin D-nivåer i de Svenska och Etiopiska 
studiegrupperna, men vi fann ingen koppling till tarmdriven inflammation, eller 
behandlingseffekt avseende tarmflora, inflammatorisk aktivering eller mikrobiella metaboliter, 
trots normaliserade vitamin D-nivåer. Förhöjda TMAO nivåerna kan utgöra en bidragande risk 
för utveckling av hjärt- och kärl sjukdom hos patienter med njursvikt, men är samtidigt starkt 
kopplade till grad av njurfunktion, vilket gör att tolkning måste göras med försiktighet. För 
HIV-infekterade individer tycks TMAO nivåer påverkas både av HIV, tarmflora, likväl som 
HIV-behandling och lokal inflammation i tarmen, vilket inte utesluter, men minskar dess 
användbarhet som en biomarkör för dysbios och risk för hjärt- och kärlsjukdom i HIV.  
LIST OF SCIENTIFIC PAPERS 
I. Catharina Missailidis, Jonas Höijer, Maria Johansson, Lena Ekström, Göran Bratt,
Bo Hejdeman, Peter Bergman. Vitamin D status in well controlled Caucasian HIV
patients in relation to inflammatory and metabolic markers – a cross sectional
cohort study in Sweden. Scandinavian Journal of Immunology, 2015, 82, 55-62
II. Catharina Missailidis, Jenny Hällqvist, Abdel Rashid Qureshi, Peter Barany, Olof
Heimbürger, Bengt Lindholm, Peter Stenvinkel, Peter Bergman.Serum
Trimethylamine-N-Oxide is strongly related to renal function and predicts outcome
in chronic kidney disease. PloS one, 2016, 11.e.0141738
III. Catharina Missailidis, Ujjwal Neogi, Peter Stenvinkel, MariusTroseid, Piotr
Nowak, Peter Bergman The microbial metabolite TMAO in association with
inflammation and microbial dysregulation in three HIV cohorts at various disease
stage. AIDS, 2018, 32, 1589-1598
IV. Catharina Missailidis, Nikolaj Sørensen, Senait Ashenafi, Wondwossen Amogne,
Endale Kassa, Amsalu Bekele, Meron Getachew, Nebiat Gebreselassie, Abraham
Aseffa, Getachew Aderaye, Jan Andersson, Susanna Brighenti, Peter Bergman.
Vitamin D and phenylbutyrate supplementation does not modulate gut derived
immune activation in HIV-1. In manuscript
CONTENTS 
1 Introduction ..................................................................................................................... 1 
2 Background ...................................................................................................................... 3 
2.1 Inflammaging in HIV-1 and CKD ........................................................................ 3 
2.2 Gut barrier dysfunction in HIV-1 and CKD ......................................................... 4 
2.3 Markers of microbial translocation ....................................................................... 5 
2.4 Gut microbiome ..................................................................................................... 5 
2.5 Dysbiosis in HIV-1 and CKD ............................................................................... 6 
2.6 Trimethylamine-N-Oxide ...................................................................................... 8 
2.7 Vitamin D .............................................................................................................. 9 
2.8 Vitamin D and antimicrobial peptide LL-37 ...................................................... 10 
2.9 Vitamin D and gut epithelial barrier ................................................................... 11 
2.10 Vitamin D and the gut microbiome .................................................................... 11 
3 Aims ............................................................................................................................... 13 
4 Methodological considerations ..................................................................................... 14 
4.1 Selection of study populations ............................................................................ 14 
4.2 LL-37 ELISA ....................................................................................................... 15
4.3 Microbiome analysis ........................................................................................... 16 
4.4 Statistical analyses ............................................................................................... 17 
5 Results and discussion ................................................................................................... 18 
5.1 Paper I .................................................................................................................. 19 
5.2 Paper II, & III ...................................................................................................... 21 
5.3 Paper IV ............................................................................................................... 27 
6 Overall conclusions ....................................................................................................... 28 
7 Future perspectives ........................................................................................................ 29 
8 Acknowledgements ....................................................................................................... 31 
References ............................................................................................................................. 33 
LIST OF ABBREVIATIONS 
ART Antiretroviral treatment 
CKD Chronic kidney disease 
CVD Cardiovascular disease 
MT Microbial translocation 
AMPs Antimicrobial peptides 
LPS Lipopolysaccharide 
LBP Lipopolysaccharide binding protein 
sCD14 Soluble cluster of differentiation 14 
SCFAs Short-chain fatty acids 
VDR Vitamin D receptor 
VDBP Vitamin D binding protein 
IDO1 indoleamine 2.3-dioxygenase 
TMAO Trimethylamine-N-Oxide 
hsCRP High sensitivity CRP 
IL interleukin 
PCR Polymerase chain reaction 
NGS Next generation sequencing 
ELISA Enzyme linked immunosorbent assay 
Rtx Renal transplantation 
RCT Randomized controlled trial 
IBD Inflammatory bowel disease 
1 
1 INTRODUCTION 
Despite effective viral control through modern antiretroviral treatment (ART) HIV-1 infected 
individuals still demonstrate a still demonstrate a persistent immune activation with premature 
ageing and elevated risk for cardiovascular disease (CVD) [1]. One contributing factor to 
chronic immune activation is translocation of microbial products from the gut where HIV-1 
related loss of lymphoid tissue creates a dysfunctional mucosal barrier and dysregulated gut 
microbiome that appears to prevail with treatment [2-6]. The observation that dysbiosis (i.e. 
abnormal changes in the composition of intestinal microbiota) contributes to pathogenesis of 
disease through intestinal-derived bacterial endotoxin and metabolites is also demonstrated in 
chronic kidney disease (CKD) [7-9]. 
When designing interventional trials to improve gut health it is important to address all the 
relevant players including, innate and adaptive immunity, the intestinal barrier and the 
microbiome. Vitamin D supplementation may prove a valuable addition in HIV-1 through its 
important immunomodulatory effects [10, 11], including induction of antimicrobial peptides 
(AMPs) active in the mucosal defense against pathogenic microorganisms [12-15]. Moreover, 
vitamin D plays an active part in regulating epithelial mucosal barrier integrity [16, 17], and 
there is growing evidence that vitamin D signaling is involved in shaping the gut microbiome. 
[16, 18-20].  
However, designing clinical trials aimed at healing the “leaky gut” face problems finding 
clinically relevant end-points. Established methods of measuring the degree of microbial 
translocation (MT) are flawed with methodological problems and more importantly, only 
indirectly linked to the gut. Evaluation of possible effects on CVD requires large prospective 
studies. Thus, novel and more specific markers that links microbial products with disease 
pathogenesis and underlying dysregulation of barrier function and microbiome are warranted 
In this thesis we explore the immunomodulatory effects of vitamin D on gut-derived immune 
activation and microbiome in HIV-1 and the role of Trimethylamine-N-Oxide (TMAO), a 
metabolite produced by gut bacteria with established pro-atherosclerotic properties and a driver 
of CVD in HIV-1 infected individuals and CKD patients.
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2 BACKGROUND 
2.1  INFLAMMAGING IN HIV-1 AND CKD 
“Good fences makes good neighbors” Robert Frost 
Inflammaging, defined as an age-related increase in blood inflammatory markers, is a strong 
risk factor for cardiovascular disease, type 2 diabetes mellitus, CKD, osteopenia as well as 
dementia (21). Potential mechanisms include; changes in the gut permeability and microbiome 
(22-24); immune cell dysregulation related to metabolic stress and age-related changes in 
microRNA transcription (25); and chronic infections. 
In HIV-1, inflammaging is characterized by monocyte/ macrophage activation and 
hypercoagulation caused by virally induced damage to lymphoid tissue and liver function (26). 
A prominent feature of chronic immune activation is translocation of microbial products, such 
as lipopolysaccharide (LPS), and flagellin, from a dysregulated gut (27). 
In CKD, progressive loss of kidney function is largely caused by factors unrelated to the cause 
of the initial disease (30), and is strongly associated with inflammaging (31, 32). In recent year 
focus has been put on the role of the gut microbiome where a growing body of evidence support 
Figure 1. Pathogenesis of inflammation-associated disease in HIV-infected adults. 
Deeks et al. Immunity. 2013 (155). Reprinted with permission. 
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the association between dysbiosis, gut-derived inflammation and progression of kidney disease 
(33). 
2.2  GUT BARRIER DYSFUNCTION IN HIV-1 AND CKD 
“Good fences makes good neighbors” Robert Frost 
In a healthy gut, homeostasis is maintained by the interplay between the mucosal intestinal 
barrier, the innate and adaptive immunity, and the commensal microbiome. The main purpose 
of the mucosal barrier is to protect the host against infectious microorganisms and to control 
the exchange of molecules from the intestinal lumen. Its construction involves a layer of tightly 
bound epithelial cells covered by a mucosal layer that prevents direct contact of microorganism 
and toxins with the epithelia. A healthy mucosal layer is important for the barrier function and 
provides the structural framework for epithelial and immune-cells to regulate microbial 
presence by secreting neutralizing IgA and antimicrobial peptides (AMPs).  
Underlying the mucosal barrier is the lamina propria that harbors macrophages and T 
lymphocytes (T cells) responsible for eliminating microbial pathogens that cross the mucosal 
barrier, as well as IgA producing B lymphocytes (B cells) and dendritic cells that direct the 
adaptive immune defense.  
The pathology behind gut barrier dysfunction in HIV-1 originates in the high prevalence of 
activated CD4 T cells expressing HIV-receptors such as CCR5 along the intestinal lining. 
These cells are highly susceptible to HIV infection and cell death via apoptosis or bystander 
death through pyroptosis (32, 33). Indeed, HIV infection causes rapid and massive depletion 
of CD 4 T cells, with a selective reduction of T helper CD4 cells (Th CD4 cells) (26, 34). The 
mucosal CD 4 cell department may not fully recover despite viral suppression through ART 
(35), where loss of Th17 and Th22 CD4 cells specifically, has functional consequences for the 
gut immune barrier. These cells are the main producers of the cytokines interleukin (IL)-17 and 
IL-22 that are important regulators of epithelial proliferation and AMP production (36, 37). As 
a consequence, suboptimal CD4 cells reconstitution is associated with loss of functional 
epithelial barrier integrity and increased degree of MT and systemic immune activation (38, 
39) 
In CKD, gut barrier dysfunction is believed to be caused by an adoptive mechanism where the 
colon replaces the failing kidneys as a site for excretion of end-products of purine metabolism, 
such as urea (40). Elevated levels of urea in plasma leads to overgrowth of colonic bacterial 
species capable of hydrolyzing urea into ammonia, which changes intestinal pH and promotes 
structural alterations of the gut mucosal barrier (41). 
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2.3  MARKERS OF MICROBIAL TRANSLOCATION 
Established methods of measuring the degree of microbial translocation (MT) are flawed with 
methodological problems and many are only indirectly linked to the gut. 
Direct markers of MT include pro-inflammatory components of Gram-negative bacteria such 
as; LPS, a major component of the outer cell membrane; flagellin, a structural part of the 
flagellum used to propel the bacteria; and bacterial ribosomal (r)RNA/DNA. LPS is the most 
established marker, and is routinely analyzed by the limulus amoebocyte lysate assay. The 
assay is troubled by many technical difficulties involving sampling-factors, methodological 
problems and variation in interpretation (42). Levels of flagellin and flagellin-specific 
antibodies measured by ELISA may provide a stable assessment of MT, but its use has been 
relatively limited. Bacterial RNA/DNA is analyzed through PCR of the conserved 16S 
ribosomal DNA (16SrDNA) region. In recent years numerous studies of the gut microbiome 
have been published, many with conflicting results that may be related to differences in 
sampling, storage, nucleic acid isolation, sequencing and analyses. Traditionally Sanger 
sequencing have been used with restricted specificity and sensitivity, thus limiting its 
usefulness in the context of MT. However, next generation sequencing (NGS) may improve 
the diagnostic accuracy.  
Several indirect markers are used, such as LPS-binding protein (LBP) and sCD14. LBP is an 
acute phase protein mainly produced by the liver upon LPS stimuli (43). However, LBP 
induction can also be triggered by other microbiological structures such as peptidoglycans, 
which are also found on Gram-positive bacteria (43). CD14 is a recognition receptor found 
primarily on monocytes and macrophages. Upon activation CD14 is shed, forming soluble (s) 
CD14, which is considered a marker of monocyte activation. It was initially described as a 
specific receptor for LPS (44), but the receptor also recognizes other pathogen-associated 
molecular patterns, such as peptidoglycans (45), and lipoteichoic acid from gram-positive 
bacteria and lipoproteins (46).  
2.4  GUT MICROBIOME 
“A good digestion turneth all to health” George Herbert. 
The human intestinal microbiome is composed of 100 trillion (1014 ) colony forming units 
(CFU) of commensal bacteria. The majority belong to four dominating phyla; Firmicutes, 
Bacteriodetes, Proteobacteria and Actinobacteria, of which Bacteroidetes and Firmicutes 
together comprise 90% (47, 48). These resident commensals are differentially distributed 
throughout the intestinal tract depending on bile and pancreatic secretion, peristaltic activity as 
well as oxygen and nutrient availability (49). Aerobic and facultative anaerobic bacteria from 
the Firmicutes phylum, predominantly of the Lactobacillales order (Enterococcus, 
Streptococcus) are prominent in the small intestine as well as Proteobacteria, whereas obligate 
anaerobic bacterial genus from the Bacteroidetes phylum (Bacteroides, Prevotella), Firmicutes 
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phylum (Clostridium and Lactobacillus) and Actinobacteria (Bifidobacterium) dominate in the 
colon.  
Composition of the gut microbiome varies with age, diet, geography and socioeconomic factors 
but may also be influenced by inherited factors. Family members sharing the same household 
appear to share a similar microbial composition, or enterotype (50).  
An important function of commensal bacteria is to protect the host against exogenous 
pathogens through direct and immune-mediated (indirect) mechanisms of action (51). Direct 
mechanisms include competition for nutrients but also production of inhibitory substances such 
as AMPs and bacterial toxins (bacteriocins) by commensal bacteria. Indirect mechanisms 
involves targeted activation of innate immune defenses and enhanced epithelial production of 
AMPs. Bacterial activation also regulates IgA production by B cells.  
Another important function of the intestinal microbiome is production of short-chain fatty acids 
(SCFAs) by microbial fermentation of non-digestible carbohydrates in the colon. SCFAs, such 
as butyrate, function as a direct source of nutrients for colonocytes and are essential for 
maintaining epithelial barrier functions (52). Moreover, butyrate increases intestinal vitamin D 
receptor (VDR) expression (53), induces production of AMPs (54) and modulates 
inflammation in the gut through expansion of regulatory T cells (55, 56). 
2.5  DYSBIOSIS IN HIV-1 AND CKD 
“Death sits in the bowels and bad digestion is the root of all evil “ Hippocrates 
Several studies have demonstrated reproducible differences in the gut microbiome between 
HIV-1 infected and non-HIV infected controls. The studies are heterogeneous in terms of 
sampling method (stool sample, mucosal biopsies or rectal sponge), age, gender, ethnicity and 
geographic location. Nevertheless, there is consistent report of enrichment of the phylum 
Proteobacteria and diminished levels of the phylum Bacteroidetes (3, 5, 59, 60) in HIV-1. 
Proteobacteria and several subtaxa, of the family Enterobacteriaceae (which contains 
established pathogens such as Escherichia coli, Salmonella and Shigella) have been associated 
with activation and depletion of CD4 cells, and elevated levels of circulating LPS and immune 
activation markers (IL-6, INF-ɣ and sCD14) in HIV-1 infected individuals (2, 5, 61). Microbial 
translocation of Proteobacteria has also been implicated in the rhesus macaque SIV-model (62). 
In CKD the uremic environment affects the intestinal barrier leading to bacterial dysbiosis and 
immune activation (7, 33). Although CKD related dysbiosis is less characterized than in HIV-
1, similar aspects with an increased in relative abundance of Proteobacteria of the family 
Enterobacteriaceae has been described (9).  
However, linking specific members of the microbiome to MT and immune activation is 
challenging. An alternative approach is to identify disease-specific metabolic pathways and 
microbial metabolites that contribute to pathogenesis.  
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In HIV-1, impaired mucosal immunity and MT has been associated with activation of the 
kynurenine pathway of tryptophan metabolism through the enzyme indoleamine 2.3-
dioxygenase 1 (IDO1) in antigen-presenting cells (61, 62). Data show that IDO1 activity alters 
the balance between Th 17/ Th 22 and regulatory CD4 subsets in the gut and inhibits the hosts 
ability to maintain protective IL-17-signaling important in gut epithelial health (63). Excessive 
tryptophan degradation results from IDO1 induction by interferon gamma (INF-ɣ), and other 
pro-inflammatory molecules such as LPS, but may also be related to gut dysbiosis. Interestingly 
Vujcovic-Cvijin et al. found that bacteria with the capacity to metabolize tryptophan through 
the kynurenine pathway were enriched in virally controlled HIV-infected individuals and 
correlated to kynurenine levels and plasma levels of the inflammatory cytokine IL-6 (5). 
In CKD, the microbial metabolites indoxyl sulfate and p-cresyl sulfate correlate with 
progressive kidney failure and have been considered an essential factors in the development of 
systemic inflammation and CVD. Indoxyl sulfate and p-cresyl sulfate are the respective end-
products of bacterial fermentation of tryptophan and tyrosine (64). 
8 
2.6  TRIMETHYLAMINE-N-OXIDE 
In recent year focus has been on the microbial metabolite Trimethylamine-N-Oxide (TMAO) 
as a biomarker of CVD development (65-70) and promoter of atherosclerosis (65, 66). The 
mechanism by which TMAO promotes atherosclerosis is not completely understood but 
mechanistic studies in murine models have demonstrated an effect on macrophage activation, 
foam cell formation and altered cholesterol metabolism. More recently, murine and in-vitro 
studies have linked TMAO to vascular inflammation through activation of nuclear factor-κB 
signalling and TXNIP-NLRP3 inflammasome activity in endothelial cells (71, 72) and to 
platelet hyperreactivity (73). Furthermore, TMAO has been described as a uremic toxin 
contributing to renal failure in CKD (74, 75). 
TMAO is the primary metabolite of Trimethylamine (TMA) that is produced by gut bacteria 
and further converted to TMAO by flavin-containing monooxygenase (FMO3) in the liver (66, 
69, 76, 77). Main substrates for TMAO are the essential nutrients choline and carnitine, found 
in diets rich in fat (dairy products, eggs and red meat), but it can also be converted from betaine. 
Although plasma levels of TMAO are governed both by diet, FMO3 enzyme activity and renal 
clearance (70, 78, 79), studies suggest that the gut microbial composition is directly linked to 
circulating TMAO levels in a healthy population (66, 76, 80, 81). There are two main bacterial 
pathways generating TMA in man: the CutC/D pathway (82, 83) and the Cnt A/B pathway (84, 
85). Notably, genetic components for TMA conversion are detected in the three dominating 
Figure 2. TMAO pathways. Zhu et al. Cell. 2016 (156). Reprinted with permission. 
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phyla; Firmicutes, Proteobacteria and Actinobacteria, but appear to be absent in Bacteroidetes 
(83, 86).  
Studies in HIV-1 and CKD have yielded various results on the relationship between TMAO, 
immune activation and CVD (67, 70, 87-91).  
2.7  VITAMIN D 
“Keep your fact always toward the sunshine and shadows will fall behind you” Walt Whitman. 
Vitamin D is a fat-soluble steroid that is predominantly produced in the skin by exposure to 
ultraviolet (UVB) sunlight (VD3), with a smaller proportion coming from dietary intake 
(VD2). VD2 and VD3 are hydroxylated in the liver forming 25-hydroxyvitamin D 
(25(OH)D3), which is routinely measured as a marker of vitamin D status in plasma. This 
molecule is further hydroxylated through CYP27B1(1α–hydroxylase) in the kidneys forming 
active vitamin D (1, 25(OH)D3) that exerts its biological effects through binding to the vitamin 
D receptor (VDR). VDR is a nuclear hormone receptor and transcription factor found in a 
variety of tissues. Activation of VDR through vitamin D, or other VDR binding substrates leads 
to the expression of specific gene products and post-transcriptional mechanisms. Active 
vitamin D produced in the kidney exerts its effects in an endocrine fashion. In contrast, extra-
renal activation of vitamin D occurs “as-needed”, in an intracrine, autocrine or paracrine 
fashion through local CYP27B1 activity. Similar to VDR, CYP27B1 is expressed in a variety 
of cell-types, including immune- and gut epithelial cells (92). 
Figure 3. Vitamin D pathways. Hewison et al. Clin Endocrinol (Oxf). 2012  
(157). Reprinted with permission.  
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Although there is no formal definition of what constitutes normal vitamin D levels the 
consensus at present is to consider vitamin D levels >75 nmol/L as sufficient, whereas vitamin 
D levels between 50-75 nmol/L are consider sub-optimal and levels <50 nmol/L as deficient 
(93). Vitamin D insufficiency is associated with increased risk of cardiovascular disease (94-
98) and type-1 diabetes (99, 100) in general population and with immune activation and all-
cause mortality in HIV-1 (65, 66). In HIV-1, vitamin D insufficiency is highly prevalent (101-
108) whereas little is known on the viral effects on VDR expression. Of note, studies have
shown reduced mRNA expression of VDR on immune and podocyte cells exposed to HIV in-
vitro (109, 110). Established risk factors for vitamin D deficiency/insufficiency are; old age
(103), dark skin (111), elevated BMI (111) and certain ART in HIV-1 (111-113).
At present little data has been presented on the effects of vitamin D treatment and gut barrier 
function. In mice, targeted expression of human VDR in intestinal epithelial cells protected 
against experimental colitis (114). Conversely, reduced expression of VDR correlated with 
intestinal inflammation and disease activity in patients with inflammatory bowel disease (IBD) 
(114, 115). Although small in numbers, interventional vitamin D studies in IBD suggest that 
supplementing Mb Crohn’s patients with vitamin D might be beneficial in decreasing local and 
systemic inflammation (116-118). 
2.8  VITAMIN D AND ANTIMICROBIAL PEPTIDE LL-37 
One important innate defense mechanism against microbial pathogens in the gut is the synthesis 
and secretion of AMPs from epithelia and immune cells. There are two major gene families of 
AMPs expressed in the gut; defensins and cathelicidins. Most AMPs are small cationic 
molecules that binds to and interact with the negatively charged membranes of microbes, thus 
killing a broad range of Gram-positive and Gram-negative bacteria, as well as fungi and virus 
(119). The human cathelicidins, LL-37, may also regulate inflammation, angiogenesis and re-
epithelialization essential for wound healing (120). LL-37 expression is regulated by several 
mechanisms and is either constitutive, or induced by inflammatory signals, ER stress and 
microbial exposure.  
Vitamin D signaling is a strong inducer of the expression of LL-37 and defensins in immune 
cells and keratinocytes. (121, 122). Another molecule reported to increase LL-37 abundance in 
the gut is butyrate (54). Importantly butyrate induces expression of LL-37 from gut epithelial 
cells with VDR as the main transcription factor. Since butyrate is a foul smelling gas and as 
such unsuitable for interventional studies, we previously investigated the effects of 
phenylbutyrate (PBA), a synthetic analogue to butyrate used for treatment of urea cycle 
disorders. Similar to butyrate, PBA induces expression of LL-37 with VDR as the main 
transcription factor (123). Together, vitamin D and PBA have a synergistic effect on LL-37 
expression (124). 
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2.9  VITAMIN D AND GUT EPITHELIAL BARRIER 
The VDR is highly expressed in all cells in the intestine and experimental data have shown that 
vitamin D signaling is imperative in maintaining epithelial mucosal barrier integrity by 
promoting epithelial cell differentiation and tight junction formation (17, 125-127). 
Additionally vitamin D protects against inflammation-induced injury to the intestinal barrier 
through inhibition of nuclear factor κB (NF-κB) (114, 128).  
2.10 VITAMIN D AND THE GUT MICROBIOME 
In recent years a growing bulk of evidence points to a significant role of vitamin D in regulating 
the gut microbiome. The effect is most likely host-mediated via vitamin D activation of innate 
defense mechanisms.    
In murine models, vitamin D deficiency, or genetic deletion of the VDR, results in dysbiosis 
and aggravated gut inflammation (16, 129, 130). In human the VDR gene has been identified 
as a host factor influencing the gut microbiome in a genome-wide association analysis (131), 
further strengthening the connection between vitamin D and the microbiota.  
Interventional vitamin D studies support a regulatory effect on microbiota composition where 
low vitamin D levels associates with a higher abundance of Proteobacteria that is generally 
considered pro-inflammatory, whereas successful vitamin D supplementation correlates with 
expansion of members of the Bacteroidetes phylum and decreased abundance of members of 
the Proteobacteria phylum (19, 20, 132).   
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3 AIMS 
The general aim was to assess gut derived immune activation in HIV-1 and investigate the 
modulatory effects of vitamin D supplementation on dysbiosis, mucosal barrier function and 
MT. Additionally we wanted to explore TMAO as a novel link between gut microbiome and 
inflammaging in CKD and in HIV-1. 
Aim I 
To investigate the prevalence of vitamin D insufficiency and its associations with markers of 
MT and immune activation in HIV-1 infected patients on ART to obtain the necessary 
information to design an interventional study.  
Aim II and III 
To assess the contribution of TMAO to mortality and cardiovascular risk in CKD and HIV-1 
in different disease stages and its association with glomerular filtration rate (GFR), effect of 
dialysis and renal transplantation (Rtx), as well as associations with degree of MT, immune 
activation and microbial composition.  
Aim IV 
To investigate the effects of vitamin D and PBA supplementation on gut-derived immune 
activation, and microbiome with a special focus on TMAO and tryptophan metabolism in 
treatment-naïve HIV-1 infected individuals. he laboratory analytical methods and statistical 
approaches applied in study I-IV have been described in detail in the articles. I will here focus 
on some of the methodological limitations.   
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4 METHODOLOGICAL CONSIDERATIONS 
For an overview of the study populations see table 1. 
4.1  SELECTION OF STUDY POPULATIONS 
Paper I: We performed a cross-sectional study of HIV-1 patients recruited at the HIV clinic at 
Södersjukhuset, Stockholm, Sweden during their regular 6 months HIV-1 control between 
January-August 2012. Non-HIV controls were recruited from staff at the Karolinska University 
Hospital, Stockholm, Sweden during September-December 2012. 
The cross-sectional approach is ideal to measure prevalence in a group and allows for the study 
of multiple outcomes. A cross-sectional design can demonstrate simple associations but cannot 
prove causality. Furthermore, the selection process of subjects may bias the measured effects. 
In this case recruitment of controls from staff at Karolinska University Hospital was not optimal 
as they were a) less likely to be smokers, b) more likely to have a lower MSM prevalence, 
compared with patients at the HIV clinic at Södersjukhuset that specifically caters for the inner-
city MSM community. Furthermore, in an effort to match sex and age, the controls were 
recruited following recruitment of HIV-1 infected individuals, which may have effected 
comparison of vitamin D levels between the groups.  
Paper II: In a cross-sectional study and a retrospective cohort study (ad hoc and based on 
previously collected material) we assessed CKD patients at different disease stages, recruited 
at the Karolinska University Hospital, Stockholm, Sweden.   
A cohort study is the best method to determine incidence and natural prognosis of a condition 
in a selected cohort followed over time. The cohort design allows for calculation of relative 
risk (i.e. what effect a chosen variable may have on the outcome of interest).  In contrast to the 
cross-sectional design, cohort studies can distinguish cause and effect. However, if the selected 
outcome is rare, cohort design is a less suitable method. Moreover, subject selection and loss 
of subjects to follow-up might significantly affect the outcome.  In retrospective cohort studies, 
the analyses are performed ad hoc, on already collected material, which prevents control of 
confounding variables and relevant information might be missing.  On the other hand 
retrospective analysis has the advantage of being less susceptible to selection bias.  
In this study sex and age-matched controls to the CKD population, were randomly selected 
from the population registry in Stockholm as a cross-sectional control group. Although the 
study populations were well characterized, the retrospective design prevented assessment of 
variables, such as diet and gut microbiome. Restricted sample availability also limited the 
number of new laboratory analysis.  
Paper III: Here we performed a retrospective cohort study on primary infected and chronic 
HIV-1 infected individuals recruited at the Karolinska University Hospital in comparison to 
the cross-sectional HIV cohort collected and described in paper I. Furthermore, HIV 
populations were compared with cross-sectional non-HIV cohorts consisting of household 
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members and partners of subjects in the retrospective chronic HIV cohort and the controls from 
paper I. 
Analysis of study populations collected for other purposes has inherent problems, which have 
been touched upon in the previous paragraph. Comparing different historic study populations 
adds an extra dimension due to differences in selection, sampling and methodology of previous 
analyses.  In an attempt to overcome unequal representation of HIV versus non-HIV controls 
we added external controls from paper II, specifically selected to be age and sex-matched with 
the HIV population from paper I.  Similarly as paper II, restricted sample availability also 
limited the numbers of possible laboratory analyses.  
Paper IV: Here we performed a randomized, double-blind and placebo-controlled clinical trial 
(RCT) in ART-naïve HIV-1 infected individuals recruited at the pre-ART clinic, Department 
of Internal Medicine, Black Lion University Hospital in Addis Ababa, between 2013 and 2015. 
A well-performed RCT provides the ultimate tool to evaluate the effect of a selected exposure. 
A prospective RCT eliminates confounding variables by randomizing exposure and thus 
ensuring that confounding variables are present in equal numbers in both groups. However, 
selection bias may still affect outcome. In this case the study was dominated by women, 
possibly reflecting gender differences in willingness to screen for HIV-1 and interest in medical 
controls. Often sicker individuals are less inclined to participate in trials and fail to comply to 
the treatment protocol with ensuing loss to follow-up. In this study the inclusion criteria 
excluded individuals with severe HIV-1 related immunosuppression and co-infection with 
tuberculosis.  There was a substantial loss to follow-up from the randomized “intention to treat” 
(ITT)-population (from 278 to 197 subjects in the modified ITT), primarily related to delayed 
laboratory reports for viral load and CD4 cell counts that failed to meet inclusion criteria. From 
the modified ITT cohort, 14 subjects became ineligible for continued participation because of 
ART start and 16 subjects was lost to follow-up. The final per-protocol cohort consisted of 187 
individuals.  
4.2  LL-37 ELISA 
In paper IV a previously established in-house enzyme-linked immunosorbent assay (ELISA) 
was used for assessment of plasma-levels of LL-37 (124). In brief, microtiter plates were coated 
with a monoclonal anti-LL-37 antibody (5 μg/ml) and incubated overnight. Synthetic LL-37 
(Innovagen, Lund Sweden) standards and samples were then added and incubated overnight. 
After washing, biotinylated rabbit anti-LL-37 (1 μg/mL) (Innovagen) was added. After 
incubation and washing, the samples were incubated with Streptavidin-alkaline phosphatase 
conjugate (Chemicon, Melbourne, Australia) with four-methylumbelliferyl phosphate as 
substrate (Molecular Probes, Europe BV, Leiden, the Netherlands). The plates contained 
subject samples for both time-points with an equal distribution of treatment and placebo plated 
in duplicates, as well as negative and positive controls.  
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Despite adequate standards and subject replicates the read-outs had considerable variations 
between subjects and trial runs, making any analyses other than comparison of intra-subject 
effect difficult. Possible explanations to this variability could have been reagents, antibodies or 
human errors. 
Methodological and analytical difficulties regarding LPS and sCD14 have been commented 
upon in section 2.3.  
4.3  MICROBIOME ANALYSIS 
In recent years numerous studies of the gut microbiome have been published, many with 
conflicting results that may be related to differences in sampling, storage, nucleic acid isolation, 
sequencing and analyses. An excellent review of possible pit-falls and considerations has been 
given by Kim et al. (133). I will here summarize some of the problems with microbiome-
analysis.  
Some of the confounding variables that needs to be taken into consideration when planning a 
microbiome study are age, gender, diet and current antibiotics or other medications, of which 
all may effect gut microbial composition. Furthermore, sampling techniques (fecal stool 
sample, rectal swab or mucosal biopsies) may produce different results as they essentially 
represent different microbial niches.  
Differences in the storage and handling of samples may result in changes in the microbiome. 
To avoid changes in the original sample prompt freezing after sampling, or the use of 
alternative preservative methods is recommended.  Moreover, samples may be contaminated 
by reagents and procedures in the laboratory setting. This may severely impact results, 
especially if the extracted microbial biomass is low, which allows contaminants to dominate in 
the sequence read-out. To evaluate the degree of contamination every analysis should include 
a negative and a positive control.   
Analyses of extracted samples through high-throughput sequencing of 16srDNA genes faces 
other problems, primarily lack of species-specificity and overestimation of the number of taxa. 
Most sequencing involves universal primers binding to the conserved regions of the 16srDNA 
gene present in all bacteria. The amplified gene products allow for identification of bacterial 
taxa through comparison of hypervariable regions of the 16S rDNA gene.  
Taxonomic identification is limited by the size of the reference database used and the length of 
the fragment sequenced. Most next-generation sequencers do not generate full-length 
sequences but focuses on specific variable regions, which limits the classification process since 
there simply might not be enough genetic information to assign bacterial species names.  
Following gene sequencing the data has to undergo extensive bioinformatic processes to 
generate interpretable data. To determine which taxa that might associate with a difference in 
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phenotype multiple corrections are performed and the choice of method in controlling for 
multiple comparisons might also effect the final interpretation.  
In the microbiome analyses in paper III and IV there was no information on diet which might 
affect the interpretation of data in the HIV-1 infected individuals. In paper III the recruitment 
of household members and partners as non-HIV controls partly eliminated diet as a variable in 
comparative analyses, assuming that household members shared their foods. Furthermore, in 
both paper III and IV inclusion criteria prevented from use of antibiotics. There was, however, 
no follow-up on the use of antibiotics during the study period in either population. 
In paper IV sequence analysis of 16S rDNA on mucosal samples revealed a disproportionate 
amount of operational taxonomic units (OTUs) belonging to Pseudomonas and Halomonas 
genera. These bacteria are normally not highly present in the gut and were interpreted as 
contaminants from the sampling procedure (endoscopic biopsies), as the negative controls 
showed no contamination. After removal of contamination, there was a substantial loss of data 
specifically in the treatment group limiting conclusive results.  
4.4  STATISTICAL ANALYSES 
Choice of statistical method is based on the underlying question one wishes to study but it is 
also determined by sample size, distribution and variables. A small sample size limits the 
strengths of statistical analyses and the number of variables that can be addressed in multiple 
regression analysis. Furthermore, a small sample size is more likely to not meet the assumptions 
of normal distribution, which is a requirement for parametric tests, whereby choice of analyses 
is limited to non-parametric tests that inherently have less statistical power. A variable with a 
high degree of variability and extreme outliers is also subjected to non-parametric testing. The 
challenges when analyzing the results in study I-IV, were mainly related to small data sets with 
different populations with non-normal distribution and missing data. 
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5 RESULTS AND DISCUSSION 
Table 1. An overview of study populations 
Study 
design 
Cross-sectional Cross-
sectional 
Cross-
sectional 
Cross-
sectional 
Retrospective 
cohort 
Retrospective 
cohort 
Retrospective 
cohort 
Cross-
sectional  
RCT 
Chronic HIV CTRL  CKD 3-4 CRTL CKD 5 Primary HIV ART-naïve HIV CRTL  HIV 
Included in 
paper 
I, III I, III II II, III II III III III IV 
Subjects 
(Number)  
101  30 58 80 116 17 22 9 167 
In/exclusion 
criteria 
Subjects (age 
30-60) with well 
controlled HIV-
1 on ART with 
undetectable VL 
(< 20 
copies/mL) for > 
6 months. 
Sex-
matched 
HIV-1-
negative 
subjects 
(age 25-
67)  
Subjects 
(age 23-
79) with
CKD 
stage 3-4 
Age and 
sex-
matched 
subjects 
(age 22-
80 ) 
randomly 
selected 
by the 
Statistics 
Bureau 
of 
Sweden 
Subjects (age 
20-78) with 
end-stage 
renal failure 
(CKD 5) were 
recruited 
close to start 
of dialysis 
treatment. 
Subjects (age 
27-53) ART-
naïve with 
primary HIV-
1infection. 
Subjects (age 
19-61) ART-
naïve with 
chronic HIV-
1infection. 
Age and 
sex-
matched 
HIV-1-
negative 
subjects 
(age 28-
62) 
consisting 
of 
household 
members 
and 
partners 
of the 
patients 
Subjects 
(age 19-
62), 
ART-
naïve 
with 
confirmed 
HIV-1 
infection 
Co-
variables 
Age, sex, 
Caucasian 
origin. MSM 
HIV-years, ART 
years, pre-ART 
CD4-count, pre-
ART VL, years 
with 
undetectable 
VL, Use of 
protease 
inhibitor/NNRTI 
Age, sex, 
Caucasian 
origin.  
Age, 
sex, 
BMI, 
smoking, 
diabetes, 
CVD, 
SGA-
score 
Age, sex, 
BMI, 
smoking, 
diabetes, 
CVD, 
SGA-
score 
Age, sex, 
BMI, 
smoking, 
diabetes, 
CVD, SGA-
score 
Age, sex, 
Caucasian 
origin. MSM,  
CD4-count, VL, 
Use of protease 
inhibitor/NNRTI 
Age, sex, 
Caucasian 
origin. MSM,  
CD4-count, VL, 
Use of protease 
inhibitor/NNRTI 
Age, sex, 
Caucasian 
origin. 
Age, sex, 
BMI, 
CD4-
count, 
VL,  
Patients 
samples 
analyzed 
Plasma 
Fecal stool-
samples 
Plasma Heparin Heparin Heparin Plasma Plasma 
Fecal stool- 
samples 
Plasma 
Fecal 
stool- 
samples 
Plasma 
Colon- 
biopsies 
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5.1  PAPER I 
Based on the hypothesis that vitamin D supplementation may modulate gut immune barrier 
dysfunction and gut related immune activation, we performed a cross-sectional study of the 
prevalence of vitamin D insufficiency and its associations with markers of MT and systemic 
inflammation in HIV-1 infected patients on ART and non-HIV controls, to have the necessary 
information to design an interventional study. For detailed demographics see table I.  
We found that vitamin D levels were similarly distributed and equally low in both HIV-1 
patients and non-HIV controls. The majority had insufficient levels (vitamin D ≤ 75nmol/L) 
(HIV 84%, controls 83%) (Fig 4a). HIV-1 infected individuals did not differ in LPS levels but 
demonstrated increased immune activation in the form of elevated levels of hsCRP and sCD14 
(Fig 4b, c, d) with HIV as an independent risk factor (Table 2). There were no associations 
between vitamin D and markers for MT and immune activation or dyslipidaemia present in the 
HIV population. 
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Table 2.Regression analyses of predictors for CRP, or sCD14 in HIV patients. 
Inflammation marker Independent variable Estimate 95 % CI P-value
hsCRP (model 1) HIV 1.50 (0.59, 2.40) 0.001 
hsCRP (model 2) HIV 1.46 (0.42, 2.50) 0.006 
Vitamin D -0.00 (-0.02, 0.01) 0.704 
Age 0.00 (-0.05, 0.05) 0.915 
BMI 0.17 (0.03, 0.30) 0.017 
Smoker 0.47 (-0.46, 1.41) 0.321 
sCD14 (model 1) HIV 0.368 (0.242, 0.493) <0.001 
sCD14 (model 2) HIV 0.394 (0.247, 0.540) <0.001 
Vitamin D 0.001 (-0.003, 0.005) 0.573 
Age -0.004 (-0.012, 0.004) 0.375 
BMI -0.009 (-0.031, 0.013) 0.431 
Smoker 0.008 (-0.196, 0.212) 0.940 
Due to a skewed distribution hsCRP was analyzed by logistic regression. Linear regression was used for 
sCD14. 
Figure 4. 
Comparison of vitamin D (a); 
LPS (b); hsCRP (c); and 
sCD14 (d).in HIV-1 and non-
HIV controls.  
Values represented by median 
(10th -90th percentile). P-
values calculated by Mann-
whitney u-test. 
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Vitamin D insufficiency was highly prevalent in both HIV-1 and non-HIV controls in our 
material, which is comparable to the results from several vitamin D studies in HIV-1 
populations, as well as a population-based Swedish study from the Gothenburg region (116, 
134). However, in contrast to many of the previous cross-sectional studies in HIV-1 we found 
no significant links between vitamin D and degree of measured immune activation. There are 
many possible explanations for this difference.  
First, in the HIV-1 population studies of Legeai et al and Ansemant et al, vitamin D deficiency 
(here defined as < 25 nmol/L) associated with hsCRP and IL-6. But this association was 
weakened in multiple regression analyses where vitamin D deficiency mainly associated with 
smoking, severe immunosuppression and co-infections with hepatitis B and C (102, 108). Since 
these conditions are known to be associated with a high degree of MT and systemic 
inflammation the relation between vitamin D, hsCRP and IL-6 remains less clear. In contrast, 
our HIV-1 study population had well-controlled viremia, a normalized CD4 cell count and 
patients with hepatitis and other inflammatory or infectious conditions were excluded.  
Second, the difference may also be related to race and genetic polymorphisms where the 
population of Legeai et al. and Ansemant et al., were of mixed ethnicity (102, 108), whereas 
our study population was strictly Caucasian. The majority of circulating 25(OH)D vitamin is 
bound to vitamin D binding protein (VDBP) and albumin, and only the unbound fraction of 
vitamin D is functionally active. A study of Afro-Americans found that genetic polymorphism, 
not only explained the lower levels of 25(OH)D vitamin frequently observed in populations of 
African descent, but that it also affected expression of VDBP. Importantly, bioavailable 
vitamin D levels in the Afro-American population were similar to whites when DBP levels 
were taken into account, pointing to the inherent difficulties in estimating vitamin D related 
effects based on 25(OH)D levels alone (135).  
Finally and similar to previous studies, we found increased levels of hsCRP and sCD14 in the 
HIV-1 population despite successful viral suppression through ART (136-138). In contrast we 
did not find elevated LPS-levels as a marker for MT, suggesting that MT may not play a 
dominant part as a driver of immune activation in this population. Also, although there is good 
evidence that MT is a contributory factor to immune activation, few of the common biomarkers 
are entirely specific for MT, or epithelial disruption in the gut. LPS is believed to be a major 
trigger of monocyte activation and sCD14 release, but other components such as gram-positive 
bacteria and inflammatory cytokines can also induce release of sCD14. Of note, few studies 
have found an association between LPS and sCD14 other than in immunosuppressed HIV-1 
populations (139). Taken together evidence suggest that these two markers may reflect 
different pathologic pathways and sCD14 should not necessarily be regarded as an MT marker. 
Furthermore, although we did not find any correlation, smoking has been independently 
associated with immune activation measured by hsCRP and sCD14 in general as well as HIV-
1 populations (140-142).  
Considering the interest of therapeutic approaches aimed at reversing intestinal damage in 
HIV-1, it is important to find additional biomarkers that are better at evaluating the restoration 
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of gut immune barrier function and underlying pathology. Answering to this knowledge-gap, 
a recently published study addressed whether soluble Dipeptidylpeptidase 4 (sDPP4) levels 
could be used as a systemic marker of intestinal Th17 levels and gut immune damage during 
HIV-1 infection. DPP4 (also known as CD26), is a membrane-associated enzyme on CD4 cells 
with a specifically high expression on Th17 cells. Notably, levels of the soluble form, sDDP4, 
were decreased in primary and suppressed HIV-1 infection. Further, IL-21 treatment in a non-
human primate model restored circulating sDPP4 levels and this increase was associated with 
restoration of the Th17 cell compartment and reduced inflammation in the gut mucosa (143), 
thus suggesting that circulating sDPP4 could be used as a surrogate marker for HIV-induced 
intestinal damage. 
5.2  PAPER II, & III 
With the hypothesis that TMAO may constitute a novel link between gut microbiome and 
inflammaging in CKD and in HIV-1- patients, we assessed contribution of TMAO to mortality 
and risk of cardiovascular events, in cross-sectional and retrospective cohorts of CKD (paper 
II) and HIV-1 (paper III)-patients at various disease stages. In addition we studied its
association with glomerular filtration rate (GFR), effect of dialysis and renal transplantation
(Rtx), as well as associations with degree of MT, immune activation and microbial
composition. For demographic data see table I
We found that elevated TMAO associated with increased systemic inflammation measured by 
hsCRP and was an independent predictor of mortality in CKD 3-5 patients (Fig 5 a, b and 
Table 3). TMAO levels were strongly associated with renal function in CKD-patients and 
normalized after renal transplantation (Fig 6).  
In HIV-1, TMAO levels increased significantly after ART-initiation, but never exceeded non-
HIV controls (Fig 7). Subjects without an increase in TMAO levels after ART had; lower 
CD4/CD8 ratio at baseline (BL); a more pronounced gut dysbiosis at follow-up (FU) 
characterized by loss of Bacteroidetes; and significantly elevated LPS levels at FU (Fig 8 a-d). 
TMAO levels correlated inversely with Bacteroidetes (Rho: -0.62, P=0.002), and positively 
with Firmicutes (Rho: 0.65, P=0.001), but held no correlation to established TMA-producing 
genera. TMAO levels were not predicted by ART, immune status or degree of systemic 
inflammation in any cohort. Elevated TMAO-levels did not predict cardiovascular events in 
well-controlled HIV-1 (HR 2.76: 95% CI 0.29-26.70, p=0.38) 
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Table 3. Cox proportional hazards analysis of plasma TMAO levels stratified by tertiles 
in predicting risk of all-cause mortality at 5 years in CKD 3–5 patients. 
Variable HR (95% CI) P-value
Middle (32.2-75.2 µM/L)+ high tertile (>72.2 µM/L) 6.29 (2.67-14.8) <0.0001 
+gender+age 6.16 (2.59-14.7) <0.0001 
+gender+age+dm 8.23 (2.90-23.4) <0.0001 
+gender+age+dm+hsCRP 6.68 (2.33-19.1) 0.0004 
+gender+age+dm+hsCRP+GFR 4.32 (1.32-14.2) 0.016 
Abbreviations: DM, diabetes mellitus; hsCRP, high sensitivity CRP; GFR, glomerular filtration rate 
Figure 5. 
Elevated TMAO levels in 
CKD 3-5 patients; associated 
with an inflamed status 
(hsCRP ≥10 mg/L) (a); and 
predicted risk for all-cause 
mortality in Kaplan-Meier 
analysis (b).   
Boxplots represented by 
median (10th-90th 
percentile). P-values 
calculated by Mann-whitney 
u-test.
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Figure 6. 
TMAO levels in CKD stage 3-5, compared to healthy controls (a, c, and e), and end-stage renal disease 
patients recruited before start of dialysis (baseline), and reassessed 12 months after start of dialysis 
and/or 12 and 24 months after renal transplantation (b, d and f).  
Values expressed as median (10-90th percentile). P-values analyzed by Kruskal-Wallis’ on-way 
ANOVA, followed by Dunn’s multiple comparison test.  
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Figure 7. 
TMAO levels in; primary 
infected and chronic HIV-1 
infected individuals followed 
from baseline (BL) to follow-
up (FU) after 4-10 months ART 
treatment; and chronic HIV-1-
infected individuals on long-
term ART (chronic ART) and 
healthy controls (CTRL). 
P values are generated by 
Wilcoxon signed-rank (BL-
FU) and Mann-Whitney U test.  
Figure 8. 
Differential change in plasma 
TMAO levels after ART 
initiation (Δ TMAO: follow-up 
(FU) – baseline (BL) ) (a) in 
relation to CD4/CD8 ratio at 
baseline (b), microbial 
composition (c), and LPS levels 
at follow-up (d)..  
P values are generated by 
Wilcoxon signed-rank test (a) and 
Mann-Whitney U test (b, d).  
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In line with our hypothesis we found that TMAO levels did indeed correlate with hsCRP in 
CKD, but did not observe any association between TMAO and inflammatory biomarkers in 
HIV-1 regardless of disease stage. In fact, few other studies have found a clear correlation 
between TMAO and inflammatory markers known to predict cardiovascular risk. In contrast, 
TMAO was inversely correlated with inflammatory markers in CKD patients on haemodialysis 
(91). However, a recent study on HIV-1 infected individuals found that TMAO was positively 
associated with serum sCD14, sCD136 (both markers of monocyte activation and macrophage 
inflammation) and kynurenine/tryptophan ratio, in multiple regression analyses (144).  
Similar to our results, Tang et al. found that TMAO levels increased with CKD and predicted 
poorer long-term survival (74). Stubbs et al. and Kim et al. found that elevated TMAO was an 
independent predictor for cardiovascular events and predicted long-term mortality in CKD 
independent of traditional cardiac risk factors (70, 145). However, other studies suggest a 
confounding role of TMAO and that the association between TMAO and adverse 
cardiovascular events may in part be driven by impaired kidney function and poor metabolic 
control (146). TMAO has since many years been identified as a uremic toxin that accumulate 
with renal insufficiency. A causal link between TMAO and renal fibrosis, related to its effects 
on the transforming growth factor-β (TGFβ)-SMAD3 signaling axis, has recently been 
demonstrated in murine models (73), thus adding another layer of difficulty in interpreting the 
cause and effect of TMAO in CKD. 
In HIV-1, the support for TMAO as a major driver of adverse cardiovascular events is relatively 
weak (87-90), with the exception of the study of Shan et al. that not only observed a correlation 
with TMAO and inflammation, but also found that elevated TMAO associated with 
progression of carotid artery atherosclerosis in HIV-1 (144). In contrast to our study and 
previous studies of more limited sample size, the results of this study is based on 520 HIV-1 
infected individuals followed over 7 years. However, the study did not address renal function 
as a possible confounder. Nor did they have information regarding clinical CVD events 
although carotid artery atherosclerosis is a predictor of CVD events. Of note, no study has 
demonstrated higher TMAO levels in HIV-1 populations compared to non-HIV controls. On 
the contrary, we found that TMAO levels were decreased in untreated HIV and only normalized 
with treatment.  
Furthermore, contrary to our hypothesis we did not find evidence that gut dysbiosis in CKD 
and TMAO would lead to elevated TMAO. Previous studies have demonstrated that gut 
microbiome regulates TMAO levels (73) and that TMA converting enzymes are found in 
Firmicutes, and Proteobacteria but appear to be missing in Bacteroidetes (82, 83, 86). Studies 
of the microbiome in CKD have demonstrated increased prevalence of Proteobacteria with 
TMA converting capacity (9, 147) suggesting that gut microbiota may contribute to the net-
impact of circulating TMAO in CKD. There are, however, no studies assessing gut microbiome 
and TMAO in CKD available at present. Similar to the study by Stubbs et al. (70) we found 
that TMAO levels normalize with transplantation, which does not support a dominating role of 
the microbiome in regulating TMAO levels in CKD.  
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In HIV-1, we failed to find a clear correlation between circulating TMAO and composition of 
gut microbiota, despite increased prevalence of bacteria from the Proteobacteria and decreased 
bacteria from the Bacteriodetes phylum after ART treatment that theoretically would suggest 
an increased prevalence of TMA converting bacteria in the gut. In fact, the lack of TMAO gain 
after treatment was associated with signs of a more disturbed microbiota and increased MT, 
suggesting that TMAO levels in HIV-1 might be affected both by HIV-1 infection, ART, as 
well as microbiome and local gut inflammation  
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5.3  PAPER IV 
To investigate the effects of vitamin D and PBA supplementation on gut-derived immune 
activation, and microbiome with a special focus on TMAO and tryptophan metabolism in HIV-
1, we performed a double-blind, randomized and placebo-controlled trial of daily 
supplementation with 5000 IU vitamin D and 500 mg PBA in treatment-naïve HIV-1-infected 
individual in Addis Abeba, Ethiopia,. For demographics see table I. 
At inclusion the majority of the subjects were vitamin D insufficient (92%). Vitamin D levels 
increased significantly after 16 weeks of supplementation, proving high treatment efficacy. 
However, and in contrast with our hypothesis, treatment failed to produce significant effects 
on circulating immune activation markers sCD14, LL-37, or levels of TMAO and 
kynurenine/tryptophan ratio. Nor was there a significant treatment effect on the colonic 
mucosal microbiome with regard to alpha diversity measured by number of operational 
taxonomic units and Shannon microbial diversity index, or in beta diversity measured by 
principal component analyses.  
The choice of combining vitamin D and PBA was to increase LL-37 production from epithelial 
cells and macrophages, as previously described (148), thus strengthening the mucosal defences. 
However, the combination also infers interpretational difficulties. The role of circulating LL-
37 remains to be defined, but has been used by others as a surrogate marker for vitamin D effect 
on innate immunity. Surprisingly we did not find that supplementation increased LL-37 levels 
in plasma as previously described (149, 150). It is possible that the lack of effect on LL-37 in 
our study in part can be explained by methodological problems with an LL-37 assay that 
showed great inter-individual variations. In addition, it is possible that the combination with 
PBA, by virtue of its role as an HDAC-inhibitor (151), may have reactivated latent HIV (152), 
thus confounding the desired outcomes. One may also speculate if un-controlled viremia 
opposed the modulatory effects of vitamin D and PBA through downregulating of the VDR 
receptor, as described in studies of human podocytes and T and NK cells exposed to HIV in-
vitro (109, 110). In addition, a recent study demonstrated that in-vitro stimulation with butyrate 
increased IDO1 activity in macrophages (153). Although this has not been studied with PBA, 
which is a synthetic butyrate analogue, the lack of reduction of the kynurenine/tryptophan-ratio 
might be related to a similar IDO1-stimulating effect. 
Finally, the cohort selection represent HIV-1 infected individuals of relatively good immune 
status where dysbiosis, and gut derived inflammation may be less advanced, thus making 
possible treatment-effects too small to detect. 
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6 OVERALL CONCLUSIONS 
Well-controlled Swedish HIV-1 infected individuals were subjected to increased immune 
activation measured by elevated hsCRP and sCD14 despite many years of effective treatment. 
They did not, however, display increased levels of MT measured by LPS. The results 
emphasize the need for new plasma biomarkers that more specifically represent a dysregulated 
immune gut barrier and/or underlying dysbiosis for evaluation in future treatment strategies.  
Assessment of the microbial metabolite TMAO as a novel link between gut microbiome and 
inflammaging in CKD, supports a contributory role for TMAO levels in immune activation 
and all-cause mortality. However, the role of TMAO in the cardiovascular pathogenesis in 
CKD was not specifically addressed. Moreover, elevated TMAO levels were strongly related 
to kidney functions suggesting that the effects should be interpreted with caution. 
In HIV-1, TMAO levels were lower in untreated individuals and normalized with treatment, 
but held no association with immune status, markers of immune activation or MT. Nor did 
TMAO levels clearly associate with gut microbiome, or degree of dysbiosis. Although the 
cardiovascular risks associated with elevated TMAO have been demonstrated in general 
population, our data does not support TMAO as significant link between gut dysbiosis 
inflammaging and CVD in HIV.  
Assessment of vitamin D in Swedish and Ethiopian HIV-1 cohorts found ample room for 
vitamin D supplementation, based on present recommendations regarding vitamin D levels. 
Vitamin D did not, however, correlate to degree of immune activation or MT in any cohort. 
Nor did supplementation with vitamin D and PBA effect the degree of immune activation, 
levels of TMAO and kynurenine/tryptophan-ratio or gut microbiome, despite normalized 
vitamin D levels. 
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7 FUTURE PERSPECTIVES 
Although suppressed HIV-1 infected individuals face a far less risk of severe cardiovascular 
events and other co-morbidity compared to CKD patients, the two conditions share similar 
pathognomonic features characterized by inflammaging through a dysregulated gut and 
underlying dysbiosis. However, although there certainly is mounting evidence linking the gut 
with systemic immune activation there is a paucity of knowledge regarding underlying 
microbial network. In fact, the intestine is an entire eco-system inside the human host that 
possess many qualities of an endocrine organ and our knowledge of what constitutes a healthy 
gut is still in its infancy.  
In order to better address the impact on gut derived inflammaging as a driver of multi-morbidity 
in HIV and CKD, well-controlled studies on the exact nature of gut dysbiosis, and underlying 
mechanisms, in relation to diet, lifestyle, and comorbidities, should be performed in diverse 
ethnic populations. More importantly, prospective cohort studies assessing the microbiome 
before and during disease development would bring valuable information on disease relevant 
changes.  
Another, and possibly more effective way, is to study the functional pathways of microbial 
metabolites associated with disease with the intent to tailor treatment that can “drug-the bug” 
and prevent disease development. In this regard TMAO is one of the best investigated 
substrates. Importantly, this concept has been proven efficient in a recent murine study 
demonstrating that inhibition of TMA converting enzymes in the gut reduced TMA and TMAO 
levels and protected mice from diet-induced atherosclerosis. (154). In CKD there is now a clear 
indication that TMAO may indeed contribute to CVD, outside of common risk factors, and that 
directed efforts to limit, or block TMAO mediated effects may prove a valuable treatment 
option. In contrast TMAO mediated effects does not appear to play a dominating role in HIV-
1. In addition, at present there is little data on how dysbiosis may effect TMAO production in 
humans.  
Many other microbial metabolites have been identified as contributors to disease, such as p-
cresyl, indoxyl sulfate to name but a few, but there are many candidate substrates that remain 
to be identified. Methods such as metabolomics can help identify and quantify disease-relevant 
metabolites to be tested mechanistically in-vitro and in animal models to prove causal effects. 
In HIV, immune activation and disease progression has been linked with excessive activity of 
the kynurenine pathway of tryptophan metabolism, driven by inflammation-induced IDO1. 
Interestingly, evidence now point to a contributory role of gut bacteria with capacity to 
metabolize tryptophan through the kynurenine pathway, thus presenting a potential 
interventional target.  
Finally, identifying microbial- host receptor signaling system may also prove a valuable way 
of targeting the dysregulated gut. It is clear that VDR signaling plays a profound role in gut 
homeostasis and is under both bacterial and host control. VDR is a target for SCFAs, vitamin 
D, as well as hormonal regulation. In IBD, VDR polymorphisms and down regulation of the 
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VDR element are linked with disease activity. If VDR downregulation plays an integral part in 
HIV-1 related effects on gut mucosal barrier function remains to be further investigated. The 
lack of result observed in our RCT might in part have been the result of conflicting effects of 
the combination, as well as uncontrolled viremia. Of note, results are underway from a recent 
RCT on the effect of vitamin D supplementation alone, on immune activation, Th17 cell 
frequency, gut barrier integrity and the gut microbiome (ClinicalTrials.gov Identifier: 
NCT03426592). In contrast to our study on ART-naïve individuals, the researcher have only 
included subjects on suppressive ART, which will make an interesting comparison.  
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